Previous studies have revealed a contribution of the NF-κB pathway to diabetes-induced retinal inflammation, providing a mechanistic reason to target NF-κB for the treatment of diabetic retinopathy [59]. This evidence concerns the gene NFKB1 and diabetic retinopathy.